Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-29T15:00:10.633Z Has data issue: false hasContentIssue false

22 - Iron overload associated with hemoglobinopathies

Published online by Cambridge University Press:  01 June 2011

James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah Medical Center
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah School of Medicine, Salt Lake City
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
Get access

Summary

The major cause of iron overload in persons with severe hemoglobinopathies is repeated transfusion of erythrocytes. Because body mechanisms to excrete iron are extremely limited, the short-term benefits of chronic transfusion are followed by the eventual development of iron overload and associated disorders. In some patients, especially those who also have thalassemia alleles (Chapter 21), dietary iron absorption is increased due to suppression of hepcidin production as a consequence of increased erythropoiesis or to mutations in iron regulatory genes. Prevention and treatment of iron overload in this heterogeneous group of patients has emerged as another clinical challenge in their management.

History

The advent of safe transfusion practices and the availability of erythrocytes for transfusion in some areas of the world during the twentieth century was associated with the development of iron overload in patients with several types of chronic anemia, including hemoglobinopathies. For more than five decades, the episodic use of erythrocyte transfusion to prevent or alleviate complications of hemolysis and intravascular sickling in African-Americans with sickle cell disease has increased. For more than three decades, systematic chronic erythrocyte transfusion has been used to decrease the incidence of recurrent stroke and premature death in sickle cell disease, especially in children. Hemoglobinopathy E, sometimes co-inherited with beta-thalassemia alleles, is very common in some Asian countries. Many patients require periodic erythrocyte transfusions to alleviate chronic severe anemia. Worldwide, chronic erythrocyte transfusion and improvement in other treatment modalities increase quality and length of life in some patients with severe hemoglobinopathy syndromes.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schafer, AI, Cheron, RG, Dluhy, R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319–24.CrossRefGoogle ScholarPubMed
Fung, EB, Harmatz, PR, Lee, PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle cell disease. Br J Haematol 2006; 135: 574–82.CrossRefGoogle ScholarPubMed
Fung, EB, Harmatz, P, Milet, M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multicenter study of iron overload. Am J Hematol 2007; 82: 255–65.CrossRefGoogle ScholarPubMed
Darbari, DS, Kple-Faget, P, Kwagyan, J, Rana, S, Gordeuk, VR, Castro, O. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81: 858–63.CrossRefGoogle ScholarPubMed
Bunn, HF, Forget, BG. Hemoglobin: Molecular, Genetic and Clinical Aspects. Philadelphia, WB Saunders Company, 1986.Google Scholar
Wearer, GA, Rahbar, S, Ellsworth, CA, Alarçon, PA, Forbes, GB, Beutler, E. Iron overload in three generations of a family with hemoglobin Olympia, Gastroenterology 1984; 87: 69502.Google Scholar
Eriksson, S, Lindmark, B, Hanik, L. A Swedish family with alpha 1-antitrypsin deficiency, haemochromatosis, haemoglobinopathy D and early death in liver cirrhosis. J Hepatol 1986; 2: 652.CrossRefGoogle Scholar
Jiskoot, PM, Halsey, C, Rivers, R, Bain, BJ, Wilkins, BS. Unusual splenic sinusoidal iron overload in sickle cell/haemoglobin D-Punjab disease. J Clin Pathol 2004; 57: 539–40.CrossRefGoogle ScholarPubMed
Weatherall, DJ, Clegg, JB. The β and δβ thalassaemias in association with structural haemoglobin variants. The Thalassaemia Syndromes. Oxford, Blackwell Scientific Publications. 1981; 320–95.Google Scholar
Files, B, Brambilla, D, Kutlar, A, et al. Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol Oncol 2002; 24: 284–90.CrossRefGoogle Scholar
Voskaridou, E, Douskou, M, Terpos, E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta-thalassaemia and sickle cell disease. Br J Haematol 2004; 126: 736–42.CrossRefGoogle ScholarPubMed
Barton, JC, McDonnell, SM, Adams, PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9.CrossRefGoogle ScholarPubMed
Adams, PC, Reboussin, DM, Barton, JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 17698.CrossRefGoogle Scholar
Barton, JC, Acton, RT, Dawkins, FW, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test 2005; 9: 231–41.CrossRefGoogle ScholarPubMed
Jeng, MR, Adams-Graves, P, Howard, TA, Whorton, MR, Li, CS, Ware, RE. Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease. Am J Hematol 2003; 74: 243–8.CrossRefGoogle ScholarPubMed
Viprakasit, V, Vathesathokit, P, Chinchang, W, et al. Prevalence of HFE mutations among the Thai population and correlation with iron loading in haemoglobin E disorder. Eur J Haematol 2004; 73: 43–9.CrossRefGoogle ScholarPubMed
Merryweather-Clarke, AT, Pointon, JJ, Shearman, JD, Robson, KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275–8.CrossRefGoogle ScholarPubMed
Mortimore, M, Merryweather-Clarke, AT, Robson, KJ, Powell, LW. The haemochromatosis gene: a global perspective and implications for the Asia-Pacific region. J Gastroenterol Hepatol 1999; 14: 838–43.CrossRefGoogle ScholarPubMed
Pointon, JJ, Viprakasit, V, Miles, KL, et al. Hemochromatosis gene (HFE) mutations in southeast Asia: a potential for iron overload. Blood Cells Mol Dis 2003; 30: 302–6.CrossRefGoogle ScholarPubMed
Barton, JC, Acton, RT, Rivers, CA, et al. Genotypic and phenotypic heterogeneity of African-Americans with primary iron overload. Blood Cells Mol Dis 2003; 31: 310–19.CrossRefGoogle ScholarPubMed
Conrad, ME. Sickle cell disease and hemochromatosis. Am J Hematol 1991; 38: 150–2.CrossRefGoogle ScholarPubMed
Castro, O, Hasan, O, Kaur, K, Loyevsky, M, Gordeuk, V. Hemochromatosis in non-transfused African-American patient with sickle cell anemia. Blood 1998; 92 (suppl): 13b.Google Scholar
Barton, JC, Lee, PL, Bertoli, LF, Beutler, E. Iron overload in an African-American woman with SS hemoglobinopathy and a promoter mutation in the X-linked erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Blood Cells Mol Dis 2005; 34: 226–8.CrossRefGoogle Scholar
Alarcon, PA, Donovan, ME, Forbes, GB, Landaw, SA, Stockman, JA. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med 1979; 300: 5–8.CrossRefGoogle ScholarPubMed
Kearney, SL, Nemeth, E, Neufeld, EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007; 48: 57–63.CrossRefGoogle ScholarPubMed
Kattamis, A, Papassotiriou, I, Palaiologou, D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006; 91: 809–12.Google ScholarPubMed
Origa, R, Galanello, R, Ganz, T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92: 583–8.CrossRefGoogle ScholarPubMed
Tanno, T, Bhanu, NV, Oneal, PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096–101.CrossRefGoogle ScholarPubMed
Serjeant, GR, Ashcroft, MT, Serjeant, BE. The clinical features of haemoglobin SC disease in Jamaica. Br J Haematol 1973; 24: 49101.CrossRefGoogle ScholarPubMed
Ohene-Frempong, K, Weiner, SJ, Sleeper, , et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91: 288–94.Google ScholarPubMed
Adams, RJ, McKie, VC, Brambilla, D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998; 19: 110–29.CrossRefGoogle ScholarPubMed
Adams, RJ, Brambilla, DJ, Granger, S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP Study. Blood 2004; 103: 3689–94.CrossRefGoogle ScholarPubMed
Lee, MT, Piomelli, S, Granger, S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006; 108: 8472.CrossRefGoogle ScholarPubMed
Ballas, SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38: 30–6.CrossRefGoogle ScholarPubMed
Diop, S, Mokono, SO, Ndiaye, M, Toure Fall, AO, Thiam, D, Diakhate, L. [Homozygous sickle cell disease in patients above 20 years of age: follow-up of 108 patients in Dakar.]Rev Med Interne 2003; 24: 711–15.CrossRefGoogle Scholar
Wasi, P, Na-Nakorn, S, Pootrakul, S, et al. Alpha- and beta-thalassemia in Thailand. Ann NY Acad Sci 1969; 165: 60–82.CrossRefGoogle ScholarPubMed
Rees, DC, Styles, L, Vichinsky, EP, Clegg, JB, Weatherall, DJ. The hemoglobin E syndromes. Ann NY Acad Sci 1998; 850: 334–43.CrossRefGoogle ScholarPubMed
Agarwal, S, Gulati, R, Singh, K. Hemoglobin E-beta-thalassemia in Uttar Pradesh. Indian Pediatr 1997; 34: 287–92.Google ScholarPubMed
Khanh, NC, Thu, LT, Truc, DB, Hoa, DP, Hoa, TT, Ha, TH. Beta-thalassemia/Haemoglobin E disease in Vietnam. J Trop Pediatr 1990; 43.CrossRefGoogle Scholar
Chatterjea, JB. Haemoglobinopathies, glucose-6-phosphate dehydrogenase deficiency and allied problems in the Indian subcontinent. Bull World Health Organ 1966; 35: 8376.Google ScholarPubMed
Kaltwasser, JP, Werner, E, Schalk, K, Hansen, C, Gottschalk, R, Seidl, C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998; 43: 69904.CrossRefGoogle ScholarPubMed
Cazzola, M, Borgna-Pignatti, C, Locatelli, F, Ponchio, L, Beguin, Y, Stefano, P. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997; 37: 135–40.CrossRefGoogle ScholarPubMed
Klein, HG. Transfusions with young erythrocytes (neocytes) in sickle cell anemia. Am J Pediatr Hematol Oncol 1982; 4: 162.Google Scholar
Anderson, J, Lay, H. Neocyte transfusions for thalassemia major. Transfusion 1982; 22: 539.CrossRefGoogle ScholarPubMed
Spanos, T, Ladis, V, Palamidou, F, et al. The impact of neocyte transfusion in the management of thalassaemia. Vox Sang 1996; 70: 217–23.CrossRefGoogle ScholarPubMed
Montoya, AF. Neocyte transfusion: a current perspective. Transfus Sci 1993; 14: 1476.CrossRefGoogle ScholarPubMed
Pippard, MJ, Letsky, EA, Callender, ST, Weatherall, DJ. Prevention of iron loading in transfusion-dependent thalassaemia. Lancet 1978; 1: 1178–81.CrossRefGoogle ScholarPubMed
Anderson, LJ, Wonke, B, Prescott, E, Holden, S, Walker, JM, Pennell, DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516–20.CrossRefGoogle ScholarPubMed
Treadwell, MJ, Law, AW, Sung, J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer 2005; 44: 500.CrossRefGoogle ScholarPubMed
Voskaridou, E, Douskou, M, Terpos, E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005; 84: 434–40.CrossRefGoogle ScholarPubMed
Okpala, I. Investigational agents for sickle cell disease. Expert Opin Investig Drugs 2006; 15: 833–42.CrossRefGoogle ScholarPubMed
Barton, JC. Deferasirox Novartis. Curr Opin Investig Drugs 2005; 6: 327–35.Google ScholarPubMed
Vichinsky, E, Onyekwere, O, Porter, J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501–8.CrossRefGoogle Scholar
Barton, JC. Chelation therapy for iron overload. Curr Gastroenterol Rep 2007; 9: 74–82.CrossRefGoogle ScholarPubMed
Adams, DM, Schultz, WH, Ware, RE, Kinney, TR. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol 1996; 18: 460.CrossRefGoogle ScholarPubMed
Hartwig, D, Schlager, F, Bucsky, P, Kirchner, H, Schlenke, P. Successful long-term erythrocytapheresis therapy in a patient with symptomatic sickle cell disease using an arterio-venous fistula. Transfus Med 2002; 12: 75.CrossRefGoogle Scholar
Hilliard, LM, Williams, BF, Lounsbury, AE, Howard, TH. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 1998; 59: 28–35.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Kim, HC, Dugan, NP, Silber, JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83: 1136–42.Google ScholarPubMed
Singer, ST, Quirolo, K, Nishi, K, Hackney-Stephens, E, Evans, C, Vichinsky, EP. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 1999; 14: 122.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Raj, AB, Condurache, T, Bertolone, S, Williams, D, Lorenz, D, Sobczyk, W. Quantitative assessment of ventricular function in sickle cell disease: effect of long-term erythrocytapheresis. Pediatr Blood Cancer 2005; 45: 976–81.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×